Synergetic insulin sensitizing effect of rimonabant and BGP-15 in zucker-obes rats

Zsuzsanna Literati-Nagy, K. Tory, Botond Literáti-Nagy, Ágnes Bajza, László Vígh, L. Vígh, J. Mandl, Z. Szilvássy

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Abdominal obesity is referred for as a common pathogenic root of multiple risk factors, which include insulin resistance, dyslipidemia, hypertension, and a pro-atherogenic and pro-inflammatory state. Irrespective of its psychiatric side effects, rimonabant through blocking cannabinoid-1 receptor (CB1R) induces an increase in whole body insulin sensitivity. The aim of this work was to study the effect of selected doses of another insulin sensitizer compound BGP-15, and rimonabant on insulin resistance in Zucker obese rats with a promise of inducing insulin sensitization together at lower doses than would have been expected by rimonabant alone. We found that BGP-15 potentiates the insulin sensitizing effect of rimonabant. The combination at doses, which do not induce insulin sensitization by themselves, improved insulin signaling. Furthermore our results suggest that capsaicin-induced signal may play a role in insulin sensitizing effect of both molecules. Our data might indicate that a lower dose of rimonabant in the treatment of insulin resistance and type 2 diabetes is sufficient to administer, thus a lower incidence of the unfavorable psychiatric side effects of rimonabant are to be expected.

Original languageEnglish
Pages (from-to)571-575
Number of pages5
JournalPathology and Oncology Research
Volume19
Issue number3
DOIs
Publication statusPublished - Jul 2013

Fingerprint

rimonabant
Zucker Rats
Insulin
Insulin Resistance
Psychiatry
Cannabinoid Receptors
Abdominal Obesity
Capsaicin
Dyslipidemias
Type 2 Diabetes Mellitus
BGP 15

Keywords

  • BGP-15
  • Capsaicin
  • Glucose clamp
  • Insulin resistance
  • Obesity
  • Rimonabant

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pathology and Forensic Medicine
  • Medicine(all)

Cite this

Synergetic insulin sensitizing effect of rimonabant and BGP-15 in zucker-obes rats. / Literati-Nagy, Zsuzsanna; Tory, K.; Literáti-Nagy, Botond; Bajza, Ágnes; Vígh, László; Vígh, L.; Mandl, J.; Szilvássy, Z.

In: Pathology and Oncology Research, Vol. 19, No. 3, 07.2013, p. 571-575.

Research output: Contribution to journalArticle

Literati-Nagy, Zsuzsanna ; Tory, K. ; Literáti-Nagy, Botond ; Bajza, Ágnes ; Vígh, László ; Vígh, L. ; Mandl, J. ; Szilvássy, Z. / Synergetic insulin sensitizing effect of rimonabant and BGP-15 in zucker-obes rats. In: Pathology and Oncology Research. 2013 ; Vol. 19, No. 3. pp. 571-575.
@article{68ca5fdff74a4c269d10e0536435df37,
title = "Synergetic insulin sensitizing effect of rimonabant and BGP-15 in zucker-obes rats",
abstract = "Abdominal obesity is referred for as a common pathogenic root of multiple risk factors, which include insulin resistance, dyslipidemia, hypertension, and a pro-atherogenic and pro-inflammatory state. Irrespective of its psychiatric side effects, rimonabant through blocking cannabinoid-1 receptor (CB1R) induces an increase in whole body insulin sensitivity. The aim of this work was to study the effect of selected doses of another insulin sensitizer compound BGP-15, and rimonabant on insulin resistance in Zucker obese rats with a promise of inducing insulin sensitization together at lower doses than would have been expected by rimonabant alone. We found that BGP-15 potentiates the insulin sensitizing effect of rimonabant. The combination at doses, which do not induce insulin sensitization by themselves, improved insulin signaling. Furthermore our results suggest that capsaicin-induced signal may play a role in insulin sensitizing effect of both molecules. Our data might indicate that a lower dose of rimonabant in the treatment of insulin resistance and type 2 diabetes is sufficient to administer, thus a lower incidence of the unfavorable psychiatric side effects of rimonabant are to be expected.",
keywords = "BGP-15, Capsaicin, Glucose clamp, Insulin resistance, Obesity, Rimonabant",
author = "Zsuzsanna Literati-Nagy and K. Tory and Botond Liter{\'a}ti-Nagy and {\'A}gnes Bajza and L{\'a}szl{\'o} V{\'i}gh and L. V{\'i}gh and J. Mandl and Z. Szilv{\'a}ssy",
year = "2013",
month = "7",
doi = "10.1007/s12253-013-9620-6",
language = "English",
volume = "19",
pages = "571--575",
journal = "Pathology and Oncology Research",
issn = "1219-4956",
publisher = "Springer Netherlands",
number = "3",

}

TY - JOUR

T1 - Synergetic insulin sensitizing effect of rimonabant and BGP-15 in zucker-obes rats

AU - Literati-Nagy, Zsuzsanna

AU - Tory, K.

AU - Literáti-Nagy, Botond

AU - Bajza, Ágnes

AU - Vígh, László

AU - Vígh, L.

AU - Mandl, J.

AU - Szilvássy, Z.

PY - 2013/7

Y1 - 2013/7

N2 - Abdominal obesity is referred for as a common pathogenic root of multiple risk factors, which include insulin resistance, dyslipidemia, hypertension, and a pro-atherogenic and pro-inflammatory state. Irrespective of its psychiatric side effects, rimonabant through blocking cannabinoid-1 receptor (CB1R) induces an increase in whole body insulin sensitivity. The aim of this work was to study the effect of selected doses of another insulin sensitizer compound BGP-15, and rimonabant on insulin resistance in Zucker obese rats with a promise of inducing insulin sensitization together at lower doses than would have been expected by rimonabant alone. We found that BGP-15 potentiates the insulin sensitizing effect of rimonabant. The combination at doses, which do not induce insulin sensitization by themselves, improved insulin signaling. Furthermore our results suggest that capsaicin-induced signal may play a role in insulin sensitizing effect of both molecules. Our data might indicate that a lower dose of rimonabant in the treatment of insulin resistance and type 2 diabetes is sufficient to administer, thus a lower incidence of the unfavorable psychiatric side effects of rimonabant are to be expected.

AB - Abdominal obesity is referred for as a common pathogenic root of multiple risk factors, which include insulin resistance, dyslipidemia, hypertension, and a pro-atherogenic and pro-inflammatory state. Irrespective of its psychiatric side effects, rimonabant through blocking cannabinoid-1 receptor (CB1R) induces an increase in whole body insulin sensitivity. The aim of this work was to study the effect of selected doses of another insulin sensitizer compound BGP-15, and rimonabant on insulin resistance in Zucker obese rats with a promise of inducing insulin sensitization together at lower doses than would have been expected by rimonabant alone. We found that BGP-15 potentiates the insulin sensitizing effect of rimonabant. The combination at doses, which do not induce insulin sensitization by themselves, improved insulin signaling. Furthermore our results suggest that capsaicin-induced signal may play a role in insulin sensitizing effect of both molecules. Our data might indicate that a lower dose of rimonabant in the treatment of insulin resistance and type 2 diabetes is sufficient to administer, thus a lower incidence of the unfavorable psychiatric side effects of rimonabant are to be expected.

KW - BGP-15

KW - Capsaicin

KW - Glucose clamp

KW - Insulin resistance

KW - Obesity

KW - Rimonabant

UR - http://www.scopus.com/inward/record.url?scp=84880326389&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880326389&partnerID=8YFLogxK

U2 - 10.1007/s12253-013-9620-6

DO - 10.1007/s12253-013-9620-6

M3 - Article

C2 - 23640247

AN - SCOPUS:84880326389

VL - 19

SP - 571

EP - 575

JO - Pathology and Oncology Research

JF - Pathology and Oncology Research

SN - 1219-4956

IS - 3

ER -